Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2

INTRODUCTION: The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk of progression to severe COVID-19 in high-risk patients has been demonstrated. However, evidence in infected kidney transplant recipients (KTRs) is lacking. Moreover, NR has significant and...

Descripción completa

Detalles Bibliográficos
Autores principales: Devresse, Arnaud, Sébastien Briol, De Greef, Julien, Lemaitre, Florian, Boland, Lidvine, Haufroid, Vincent, Scohy, Anais, Kabamba, Benoit, Yombi, Jean Cyr, Belkhir, Leila, Darius, Tom, Buemi, Antoine, De Potter, Kristell, Mantegazza, Rebecca, Bearzatto, Bertrand, Goffin, Eric, Kanaan, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420244/
https://www.ncbi.nlm.nih.gov/pubmed/36060621
http://dx.doi.org/10.1016/j.ekir.2022.08.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420244/
https://www.ncbi.nlm.nih.gov/pubmed/36060621
http://dx.doi.org/10.1016/j.ekir.2022.08.026

Ejemplares similares